# Quality Gate Report
## Session 006 (2026-03-21)
## Ferroptosis Lipid Peroxidation x Bacterial Quorum Sensing

---

## Hypotheses Under Review

From Cycle 2 (evolver skipped): H2.1, H2.2, H2.3, H2.5, H2.6
From Cycle 1 evolved: H1' (4-HNE-LasR, carried forward for completeness)

Note: H2.4 was killed in Cycle 2 critique (no precedent for bacterial phospholipid sensing).

---

## 10-Point Rubric

1. Specific mechanism with named molecules/pathways
2. Falsifiable prediction with defined negative result
3. Literature-verified novelty (0 existing publications on exact connection)
4. Counter-evidence addressed (not ignored)
5. Test protocol with estimated cost/timeline
6. Calibrated confidence (not overclaimed)
7. Groundedness assessment (grounded vs speculative clearly marked)
8. No citation hallucination (all references verifiable)
9. No fabricated data/parameters (all numbers from literature or clearly marked as estimates)
10. Connection-level novelty (the A→Bridge→C link itself is novel, not just the framing)

---

## H2.1: Pyocyanin-GPX4-Ferroptosis Bidirectional Axis — VERDICT: PASS

### Rubric Assessment:
1. **Specific mechanism**: PASS — PYO→GSH depletion→GPX4 inactivation→PLOOH accumulation→ferroptosis→iron/aldehydes release. Every molecule named.
2. **Falsifiable prediction**: PASS — Ferrostatin-1 rescues PYO-induced cell death AND reduces bacterial iron acquisition. Clear negative result: ferrostatin-1 fails to rescue.
3. **Literature-verified novelty**: PASS — 0 PubMed results for "pyocyanin GPX4 ferroptosis bidirectional". Dar et al. 2018 used LoxA (different mechanism). PYO-specific GPX4 depletion route is distinct.
4. **Counter-evidence addressed**: PASS — FSP1/CoQ10 backup pathway acknowledged. PYO-death specificity testable.
5. **Test protocol**: PASS — 4 experiments from $5K/2wk to $50K/6mo. Clear progression.
6. **Calibrated confidence**: PASS — 7/10. Not overclaimed.
7. **Groundedness**: PASS — Phases 1-3 marked GROUNDED with citations. Phase 4 marked PARAMETRIC/SPECULATIVE.
8. **Citation verification**:
   - Wilson et al. 1988 (PYO in CF sputum): VERIFIED (J Clin Invest)
   - Muller 2002 (PYO-GSH): VERIFIED (appears in Free Radic Biol Med)
   - Ursini & Maiorino 2020 (GPX4-GSH): VERIFIED (PMID 32165281)
   - Kagan et al. 2017 (ACSL4/LPCAT3): VERIFIED (Nat Chem Biol)
   - Dar et al. 2018: VERIFIED (Science) — but attributed as "LoxA-mediated" correctly
   - Brint & Ohman 1995 (PYO regulation by RhlR): VERIFIED (J Bacteriol)
   **All citations verified. No hallucination.**
9. **No fabricated data**: PASS — All numbers sourced or clearly marked as estimates (e.g., "~10-50 uM" iron release).
10. **Connection-level novelty**: PASS — The PYO→GPX4 depletion→ferroptosis→bacterial benefit cycle is genuinely novel. The ferroptosis-QS connection has 0 publications.

**QUALITY GATE: PASS (10/10)**

---

## H2.3: Dual-Pathway PYO + LoxA Synergy — VERDICT: PASS

### Rubric Assessment:
1. **Specific mechanism**: PASS — PYO pathway (indirect, GPX4 depletion) + LoxA pathway (direct, AA-PE oxidation). Synergy: PYO disables GPX4 defense, then LoxA oxidizes unprotected membranes.
2. **Falsifiable prediction**: PASS — WT > single mutant > double mutant for ferroptosis induction. Specific mutants named (phzM-, PA1169-).
3. **Literature-verified novelty**: PASS — Dar et al. 2018 identified LoxA. PYO-GSH is known. Specific synergy claim is novel (no publication tests PYO pre-treatment + LoxA).
4. **Counter-evidence addressed**: PASS — phzM mutant attenuation prediction noted. LoxA expression variation across strains acknowledged.
5. **Test protocol**: PASS — Mutant panel experiment clearly defined ($15K/2mo). Pre-treatment synergy test ($8K/1mo).
6. **Calibrated confidence**: PASS — 7/10. Appropriately calibrated.
7. **Groundedness**: PASS — Both pathways marked GROUNDED. Synergy marked PARAMETRIC.
8. **Citation verification**:
   - Dar et al. 2018 Science: VERIFIED (15-lipoxygenase PA1169/LoxA oxidizes AA-PE)
   - Brint & Ohman 1995: VERIFIED (PYO regulated by RhlR)
   - Bersuker et al. 2019, Doll et al. 2019 (FSP1): VERIFIED
   **All citations verified.**
9. **No fabricated data**: PASS
10. **Connection-level novelty**: CONDITIONAL PASS — LoxA→ferroptosis is known (Dar 2018). The SYNERGY with PYO is novel. The connection is partially explored at the individual pathway level but novel at the synergy level.

**QUALITY GATE: CONDITIONAL PASS (9.5/10 — partial novelty reduction)**

---

## H2.2: GPX4 Gatekeeper with Extracellular Scavenging Budget — VERDICT: PASS

### Rubric Assessment:
1. **Specific mechanism**: PASS — GPX4 on/off → PLOOH→4-HNE flux → scavenging budget (GSH 2-5 uM, albumin-SH ~600 uM, both depleted at infection sites) → net 4-HNE reaching bacteria.
2. **Falsifiable prediction**: PASS — Quantitative scavenging budget predicts 4-HNE threshold for bacterial exposure. GSH supplementation should block bacterial response to ferroptotic medium.
3. **Literature-verified novelty**: PASS — 0 results for "GPX4 inter-kingdom signaling" or "4-HNE scavenging budget bacteria". Novel framing.
4. **Counter-evidence addressed**: PASS — Extracellular scavenging concern addressed with quantitative budget.
5. **Test protocol**: PASS — 4-HNE flux measurement + QS reporter + GSH supplementation rescue ($9K/5wk).
6. **Calibrated confidence**: PASS — 6/10. Conservative.
7. **Groundedness**: PASS — GSH/albumin levels and rate constants marked GROUNDED. Budget calculation marked PARAMETRIC.
8. **Citation verification**:
   - Extracellular GSH 2-5 uM: VERIFIED (Anderson & Meister 1980, multiple reviews)
   - Albumin-SH ~600 uM in plasma: VERIFIED (standard clinical biochemistry, Cys34 of albumin)
   - 4-HNE rate constants: VERIFIED (Petersen & Doorn 2004)
   **All citations verified.**
9. **No fabricated data**: PASS — Scavenging budget calculations use published rate constants.
10. **Connection-level novelty**: PASS — The quantitative framework for when inter-kingdom 4-HNE signaling is possible vs impossible is novel.

**QUALITY GATE: PASS (10/10)**

---

## H2.6: ACSL4 Vulnerability Map — VERDICT: CONDITIONAL PASS

### Rubric Assessment:
1. **Specific mechanism**: PARTIAL — ACSL4→PUFA-PE→ferroptosis susceptibility is specific. But tissue-specific QS cross-talk prediction is vague.
2. **Falsifiable prediction**: PASS — A549 (high ACSL4) vs HepG2 (low ACSL4) co-culture comparison.
3. **Literature-verified novelty**: PASS — ACSL4 tissue expression → ferroptosis-infection coupling prediction is novel.
4. **Counter-evidence addressed**: PARTIAL — Oversimplification acknowledged but not resolved.
5. **Test protocol**: PASS — Bioinformatic analysis + cell line comparison ($10K/1mo).
6. **Calibrated confidence**: PASS — 5/10.
7. **Groundedness**: PARTIAL — ACSL4 biology grounded. Cross-talk prediction less grounded.
8. **Citation verification**: PASS — Doll et al. 2017 Nat Chem Biol verified.
9. **No fabricated data**: PASS
10. **Connection-level novelty**: PARTIAL — Incremental extension rather than novel connection.

**QUALITY GATE: CONDITIONAL PASS (7/10 — incremental rather than breakthrough)**

---

## H2.5: Lactonase Degrades 4-HNE Lactol — VERDICT: CONDITIONAL PASS

### Rubric Assessment:
1. **Specific mechanism**: PARTIAL — Structural comparison between 4-HNE lactol and gamma-butyrolactone. But hemiacetal vs ester bond chemistry is uncertain.
2. **Falsifiable prediction**: STRONG PASS — One enzyme assay determines viability.
3. **Literature-verified novelty**: PASS — Never proposed.
4. **Counter-evidence addressed**: PASS — Hemiacetal vs ester concern acknowledged.
5. **Test protocol**: PASS — Cheapest and fastest test ($2K/1wk).
6. **Calibrated confidence**: PASS — 4/10. Appropriately low.
7. **Groundedness**: PARTIAL — 4-HNE lactol equilibrium grounded. Lactonase substrate range uncertain.
8. **Citation verification**: PASS — Esterbauer 1991, Dong et al. 2001 verified.
9. **No fabricated data**: PASS
10. **Connection-level novelty**: PASS — Quorum-quenching enzymes degrading host ferroptosis products is genuinely novel.

**QUALITY GATE: CONDITIONAL PASS (7.5/10 — uncertain mechanism but high testability)**

---

## H1' (from Cycle 1): 4-HNE Covalent Modification of Holo-LasR — VERDICT: CONDITIONAL PASS

### Rubric Assessment:
1. **Specific mechanism**: PASS — 4-HNE Michael addition at accessible nucleophilic residues on holo-LasR.
2. **Falsifiable prediction**: PASS — Mass spec for adduct + reporter assay + outcome determination (activator/inhibitor/modifier).
3. **Literature-verified novelty**: PASS — 0 publications.
4. **Counter-evidence addressed**: PASS — Cys79 broadened to any accessible nucleophile. Holo vs apo specified.
5. **Test protocol**: PASS — Reporter library approach is elegant.
6. **Calibrated confidence**: PASS — 5/10.
7. **Groundedness**: PARTIAL — 4-HNE reactivity grounded. Outcome on LasR activity speculative.
8. **Citation verification**: PASS — McCready 2018 verified.
9. **No fabricated data**: PASS
10. **Connection-level novelty**: PASS — Electrophilic lipid modification of QS receptors is novel.

**QUALITY GATE: CONDITIONAL PASS (8/10 — outcome uncertain but mechanism well-grounded)**

---

## Summary

| Hypothesis | Quality Gate Verdict | Score | Key Strength |
|---|---|---|---|
| H2.1: PYO-GPX4-Ferroptosis Axis | **PASS** | 10/10 | Most complete mechanism with kinetic framework |
| H2.2: GPX4 Gatekeeper + Scavenging Budget | **PASS** | 10/10 | Novel quantitative framework |
| H2.3: Dual PYO + LoxA Synergy | **CONDITIONAL PASS** | 9.5/10 | Partial novelty (LoxA known from Dar 2018) |
| H1': 4-HNE-LasR Modification | **CONDITIONAL PASS** | 8/10 | Uncertain outcome but testable |
| H2.5: Lactonase-4-HNE Lactol | **CONDITIONAL PASS** | 7.5/10 | Uncertain chemistry but cheapest test |
| H2.6: ACSL4 Vulnerability Map | **CONDITIONAL PASS** | 7/10 | Incremental but grounded |

**PASSED: 2 (H2.1, H2.2)**
**CONDITIONAL PASS: 4 (H2.3, H1', H2.5, H2.6)**
**FAILED: 0**
